These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 12538422

  • 1. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
    Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A, Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators.
    Circulation; 2003 Jan 21; 107(2):238-44. PubMed ID: 12538422
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, 'A to Z' Investigators.
    JAMA; 2004 Jul 07; 292(1):55-64. PubMed ID: 15238591
    [Abstract] [Full Text] [Related]

  • 3. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
    Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG, INTERACT Trial Long-Term Follow-Up Investigators.
    Am Heart J; 2006 Feb 07; 151(2):373-9. PubMed ID: 16442903
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.
    Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM, Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.
    J Am Coll Cardiol; 2003 Jan 01; 41(1):20-5. PubMed ID: 12570939
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation.
    Lev EI, Hasdai D, Scapa E, Tobar A, Assali A, Lahav J, Battler A, Badimon JJ, Kornowski R.
    J Am Coll Cardiol; 2004 Mar 17; 43(6):966-71. PubMed ID: 15028351
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H, SYNERGY Trial Investigators.
    JAMA; 2004 Jul 07; 292(1):45-54. PubMed ID: 15238590
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV, Feit F, Lincoff AM, Bertrand M, Pocock S, Ware J, Ohman EM, Mehran R, Stone GW.
    J Am Coll Cardiol; 2008 May 06; 51(18):1734-41. PubMed ID: 18452778
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH, Harrington RA.
    Drugs; 1998 Dec 06; 56(6):965-76. PubMed ID: 9878986
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
    Wang TY, White JA, Tricoci P, Giugliano RP, Zeymer U, Harrington RA, Montalescot G, James SK, Van de Werf F, Armstrong PW, Braunwald E, Califf RM, Newby LK.
    Circulation; 2011 Feb 22; 123(7):722-30. PubMed ID: 21300952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.